Helicobacter pylori vaccine development in the post-genomic era: can in silico translate to in vivo.
Ferrero
R L
RL
Unité de Pathogénie Bactérienne des Muqueuses, Institut Pasteur, 28 rue du Dr Roux, Paris 75724, France. rferrero@pasteur.fr
Labigne
A
A
D000818:Animals; D000942:Antigens, Bacterial / Q000008:administration & dosage / Q000032:analysis; D001428:Bacterial Vaccines / Q000008:administration & dosage*; D005767:Gastrointestinal Diseases / Q000517:prevention & control / Q000628:therapy; D016680:Genome, Bacterial; D016481:Helicobacter Infections / Q000517:prevention & control* / Q000628:therapy; D016480:Helicobacter pylori / Q000235:genetics* / Q000276:immunology*; D020407:Internet; D051379:Mice; D020543:Proteome / Q000032:analysis; D022282:Vaccines, Acellular / Q000008:administration & dosage; D014613:Vaccines, Attenuated / Q000008:administration & dosage; D015164:Vaccines, Inactivated / Q000008:administration & dosage
D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; D020543:Proteome; D022282:Vaccines, Acellular; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated